If you've been scrolling through mental health forums or wellness clinics lately, you've probably seen ketamine IV therapy pop up as a potential game-changer for treatment-resistant depression. Unlike most psychiatric medications that take weeks to work, ketamine can produce noticeable relief in hours or days. For people who've tried multiple antidepressants without success, this is genuinely compelling. But here's what matters: the clinical evidence is real, not invented—but it's also narrower and messier than the marketing suggests. This article breaks down what we actually know from the research, who it might actually help, what it costs, and why access remains a barrier for most people.
The Clinical Evidence: What the Research Actually Shows
Ketamine IV therapy has legitimate FDA backing—sort of. The FDA approved esketamine (Spravato), a nasal spray version, for treatment-resistant depression in 2019. This approval was based on randomized controlled trials showing that around 50-70% of people with severe, treatment-resistant depression experienced significant improvement within days to weeks. That's genuinely impressive compared to traditional antidepressants, which take 4-6 weeks and fail in about 30-40% of patients. Studies published in JAMA Psychiatry, American Journal of Psychiatry, and Biological Psychiatry consistently show rapid symptom reduction—sometimes within 24 hours. However, here's the critical detail: most of these improvements are temporary without continued treatment. Ketamine appears to work best as a bridge therapy (getting you stable quickly) or as a repeated maintenance treatment, not as a one-time cure. The studies that show the best long-term outcomes involve regular infusions over months, which makes the cost and logistics pretty significant for most people.
Who Actually Benefits: It's More Specific Than General Depression
This is where the hype and reality diverge. Ketamine IV therapy shows the strongest evidence for **treatment-resistant depression**—meaning you've already failed at least two standard antidepressants. If you're on your first or second medication trial, there's honestly better evidence for staying the course with conventional options before jumping to IV therapy. Ketamine also shows promise for depression with suicidal ideation, where the rapid onset matters because someone needs relief *now*, not in six weeks. Real people on Reddit mental health communities frequently report that ketamine "saved their life" when they were actively suicidal, and the clinical literature backs this up: it's particularly effective for acute crisis situations. It also appears helpful for depression with significant anxiety. But for mild-to-moderate depression, or depression that's responsive to current meds? Ketamine IV doesn't have stronger evidence than what you're probably already using. The key question your psychiatrist should ask: "Have you genuinely optimized your current medication, or are you treatment-resistant?"
The Practical Reality: Cost, Frequency, and Access
Here's where clinical promise meets real life. A typical ketamine IV protocol starts with 6-8 infusions over 2-3 weeks, with each session costing $500-$1,200 depending on location and clinic. That's $3,000-$10,000 upfront just to see if it works. Most insurance won't cover this—Medicare technically does in limited cases, but commercial insurance largely treats it as experimental. Some legit clinics have financial aid programs, but many don't. After the initial series, you're looking at maintenance infusions every 2-4 weeks to sustain the benefits, which means this isn't a one-time investment. This is why ketamine IV therapy is still largely accessible to people with significant out-of-pocket resources or excellent insurance. The nasal spray (Spravato) is covered by some insurance plans, but it requires weekly clinic visits for monitoring, which has its own logistical burden. Real-world data from ketamine clinics shows that roughly 40-50% of people discontinue treatment due to cost or inconvenience, even if they initially responded well. That matters.
What Happens During Infusion (and the Dissociation Thing)
A ketamine IV session typically lasts 40-90 minutes. You'll be monitored by medical staff, and doses are carefully calibrated (usually 0.5-1.0 mg/kg). Most people experience dissociation—a feeling of detachment from your body or surroundings—during the infusion. Some describe it as dreamy or surreal; others find it uncomfortable. This dissociation usually resolves within 30 minutes of the infusion ending, but you can't drive yourself home. Clinics should provide transportation arrangements or require someone to pick you up. Common side effects during infusion: elevated blood pressure and heart rate (temporary), nausea, dizziness, and brief headaches. Most people tolerate it reasonably well, though Reddit threads show that dissociation experiences vary wildly—some people find it therapeutic, others say it felt disturbing. The key thing: this isn't like taking a pill at home. It requires medical supervision, dedicated time, and someone to get you home safely. That's worth factoring into the decision.
The Gaps in the Evidence: What We Don't Actually Know Yet
Despite the encouraging clinical trials, there are honest knowledge gaps. Long-term safety beyond 12-18 months isn't well-studied—most trials follow people for a year. We don't have solid data on whether repeated ketamine infusions carry risks for cognitive function or dependency (ketamine has recreational abuse potential, though clinical-grade IV therapy at medical doses is different from street use). We also don't have reliable biomarkers to predict who will respond before you start treatment. Some people respond dramatically; others show minimal improvement despite meeting all the criteria for treatment-resistant depression. Researchers are working on this, but right now it's partially trial-and-error. There's also limited research comparing ketamine IV directly to other emerging rapid-acting treatments like TMS (transcranial magnetic stimulation), which doesn't require infusions or dissociation and has growing evidence for depression. The field is evolving, and future research might reveal other options that work comparably well with fewer logistics.
Should You Actually Try It? A Practical Framework
Consider ketamine IV therapy if: you've genuinely tried and failed at least two or three antidepressants at adequate doses for adequate duration; you're experiencing suicidal thoughts and need relief soon; you have resources (time, money, or insurance coverage) for the initial protocol plus maintenance; and you've ruled out other rapid-acting options like TMS or ECT (electroconvulsive therapy, which honestly has even stronger evidence for severe depression but carries its own considerations). If you're on your first or second medication, stick with optimizing that first—adding therapy, exercise, or lifestyle changes might be all you need. If you're drawn to ketamine because wellness clinics are marketing it aggressively, take a breath. The evidence is real, but so is the cost and logistical burden. Be wary of clinics that promise 100% success or position ketamine as a replacement for ongoing psychiatric care. The best outcomes happen when ketamine IV is paired with therapy and psychiatrist oversight. Real talk: if you're considering it, have this conversation with a psychiatrist who isn't financially incentivized by selling infusions. Many ketamine-offering clinics are ethical, but the financial model creates inherent bias.
The Bottom Line
Ketamine IV therapy has genuine clinical evidence for treatment-resistant depression—stronger and faster-acting than anything else we have for that specific population. If you've legitimately failed multiple antidepressants, you're suicidal, and you have access and resources, it's worth discussing seriously with a psychiatrist. But it's not a quick fix, it's not a one-time cure, and it's not better than conventional treatment for mild-to-moderate depression. The real-world experience involves months of infusions, thousands of dollars, and ongoing psychiatric care. If the marketing hype has you thinking this is an easy solution, recalibrate. If you're genuinely treatment-resistant, educated about the commitment, and ready to combine it with other therapies, then the evidence supports giving it a shot.